AMSTERDAM, March 18 (Reuters) - The EU's drug watchdog said on Thursday it is still convinced the benefits of AstraZeneca's COVID-19 vaccine outweigh the risks following an investigation into reports of blood disorders that prompted more than a dozen nations to suspend its use. Following are reactions after the European Medicines Agency (EMA) gave an update on its views on the Oxford-AstraZeneca vaccine. "It is important that public health bodies monitor the roll out of the vaccine, and safety has to be paramount with any new medicine. The approved COVID-19 vaccines in the UK have all been through this thorough process. “Over the last few days, a number of countries decided to pause the rollout of the AstraZeneca-Oxford COVID-19 vaccine to double check that having the vaccine is not linked to any cases of blood clots.

Source: The Star March 18, 2021 16:45 UTC